The Utah Center for Bleeding & Clotting Disorders (UCBCD) at University of Utah Health was established in 2016. As the only federally-funded adult hemophilia treatment center (HTC) in the state of Utah, and in collaboration with the pediatric HTC at Primary Children’s Hospital, we are committed to providing a comprehensive medical home with state-of-the-art treatment, family-centered education and ground-breaking research to children, adolescents, and adults with hemophilia and related bleeding and clotting disorders across the state.
Our integrated care team includes board-certified hematologists, nurse coordinators, physical therapists, social workers, pharmacists and a specialized coagulation laboratory. Together, the team work to meet the specific needs of persons with bleeding disorders, as well as to enhance the overall quality of life by assisting with the prevention and management of complications associated with bleeding disorders.
Since its inception under the leadership of Dr. George Rodgers, MD, PhD, Medical Director of UCBCD at University of Utah Health, our patient volume has grown on a yearly basis. Given the increase in clinical volume, Dr. Ming Y. Lim, MBBChir, MSCR, was recruited in 2018 to further develop and expand our clinical services and community outreach.
Our integrated care team includes board-certified hematologists, nurse coordinators, physical therapists, social workers, pharmacists and a specialized coagulation laboratory. Together, the team work to meet the specific needs of persons with bleeding disorders, as well as to enhance the overall quality of life by assisting with the prevention and management of complications associated with bleeding disorders.
Since its inception under the leadership of Dr. George Rodgers, MD, PhD, Medical Director of UCBCD at University of Utah Health, our patient volume has grown on a yearly basis. Given the increase in clinical volume, Dr. Ming Y. Lim, MBBChir, MSCR, was recruited in 2018 to further develop and expand our clinical services and community outreach.
We take pride in our integrated care model that is recognized as best-in-class for people with bleeding and clotting disorders by the Maternal Child Health Bureau (MCHB) and Centers for Disease Control and Prevention (CDC). We are one of the few HTCs natonwide who are currently performing point-of-care musculoskeletal ultrasound to assist with the diagnosis and treatment of acute hemophilic joint arthropathy, an often challenging diagnosis to make.
The HTC team is currently based at the Huntsman Cancer Hospital but will be moving to the Sugar House Health Center come October 2019. To find out more about us, please visit our website.